C1q Nephropathy: The Unique Underrecognized Pathological Entity

J. Devasahayam, Gowrishankar Erode-Singaravelu, Z. Bhat, T. Oliver, Arul Chandran, Xu Zeng, P. Dakshinesh, U. Pillai
{"title":"C1q Nephropathy: The Unique Underrecognized Pathological Entity","authors":"J. Devasahayam, Gowrishankar Erode-Singaravelu, Z. Bhat, T. Oliver, Arul Chandran, Xu Zeng, P. Dakshinesh, U. Pillai","doi":"10.1155/2015/490413","DOIUrl":null,"url":null,"abstract":"C1q nephropathy is a rare glomerular disease with characteristic mesangial C1q deposition noted on immunofluorescence microscopy. It is histologically defined and poorly understood. Light microscopic features are heterogeneous and comprise minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and proliferative glomerulonephritis. Clinical presentation is also diverse, and ranges from asymptomatic hematuria or proteinuria to frank nephritic or nephrotic syndrome in both children and adults. Hypertension and renal insufficiency at the time of diagnosis are common findings. Optimal treatment is not clear and is usually guided by the underlying light microscopic lesion. Corticosteroids are the mainstay of treatment, with immunosuppressive agents reserved for steroid resistant cases. The presence of nephrotic syndrome and FSGS appear to predict adverse outcomes as opposed to favorable outcomes in those with MCD. Further research is needed to establish C1q nephropathy as a universally recognized distinct clinical entity. In this paper, we discuss the current understanding of pathogenesis, histopathology, clinical features, therapeutic options, and outcomes of C1q nephropathy.","PeriodicalId":313227,"journal":{"name":"Analytical Cellular Pathology (Amsterdam)","volume":"2 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2015-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"23","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Analytical Cellular Pathology (Amsterdam)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2015/490413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 23

Abstract

C1q nephropathy is a rare glomerular disease with characteristic mesangial C1q deposition noted on immunofluorescence microscopy. It is histologically defined and poorly understood. Light microscopic features are heterogeneous and comprise minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and proliferative glomerulonephritis. Clinical presentation is also diverse, and ranges from asymptomatic hematuria or proteinuria to frank nephritic or nephrotic syndrome in both children and adults. Hypertension and renal insufficiency at the time of diagnosis are common findings. Optimal treatment is not clear and is usually guided by the underlying light microscopic lesion. Corticosteroids are the mainstay of treatment, with immunosuppressive agents reserved for steroid resistant cases. The presence of nephrotic syndrome and FSGS appear to predict adverse outcomes as opposed to favorable outcomes in those with MCD. Further research is needed to establish C1q nephropathy as a universally recognized distinct clinical entity. In this paper, we discuss the current understanding of pathogenesis, histopathology, clinical features, therapeutic options, and outcomes of C1q nephropathy.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
C1q肾病:独特的未被认识的病理实体
C1q肾病是一种罕见的肾小球疾病,免疫荧光显微镜观察到特征性的系膜C1q沉积。它是组织学上的定义,但人们对它知之甚少。光镜下表现不均匀,包括微小改变病(MCD)、局灶节段性肾小球硬化(FSGS)和增生性肾小球肾炎。临床表现也多种多样,从儿童和成人的无症状血尿或蛋白尿到直率的肾病或肾病综合征。在诊断时高血压和肾功能不全是常见的表现。最佳治疗方法尚不明确,通常以潜在的光镜病变为指导。皮质类固醇是主要的治疗方法,免疫抑制剂保留给类固醇耐药的病例。肾病综合征和FSGS的存在似乎预示着MCD患者的不良结果,而不是有利结果。需要进一步的研究来确定C1q肾病作为一个普遍认可的独特的临床实体。在本文中,我们讨论了目前对C1q肾病的发病机制、组织病理学、临床特征、治疗选择和结果的理解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
MicroRNA-4735-3p Facilitates Ferroptosis in Clear Cell Renal Cell Carcinoma by Targeting SLC40A1 Study on the Function and Mechanism of miR-585-3p Inhibiting the Progression of Ovarian Cancer Cells by Targeting FSCN1 to Block the MAPK Signaling Pathway Transcription Factor E2F1 Exacerbates Papillary Thyroid Carcinoma Cell Growth and Invasion via Upregulation of LINC00152 Expression of Concern on “The Long Noncoding RNA LOXL1-AS1 Promotes the Proliferation, Migration, and Invasion in Hepatocellular Carcinoma” Deciphering a Novel Necroptosis-Related miRNA Signature for Predicting the Prognosis of Clear Cell Renal Carcinoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1